Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 18.86 is 36% below its 5-year average of 29.52, near the low end of its 5-year range (17.14–118.91).
As of the fiscal period ended Tuesday, June 30, 2026. 7.65% below its 12-month average of 20.42.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 18.86.
QUICK RATIO (ACID-TEST)
18.86
QUICK RATIO (ACID-TEST) AVG TTM
20.42
QUICK RATIO (ACID-TEST) AVG 3Y
25.97
QUICK RATIO (ACID-TEST) AVG 5Y
29.52
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.65%
CURRENT VS 3Y AVG
-27.36%
CURRENT VS 5Y AVG
-36.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.98
median of 626 covered companies
CURRENT VS SECTOR MEDIAN
+532.97%
vs the sector median at left
Design Therapeutics, Inc.
Market Cap
$750.73M
Quick Ratio (Acid-Test)
18.86
TTM Avg
20.42
3Y Avg
25.97
5Y Avg
29.52
Market Cap
$750.01M
Quick Ratio (Acid-Test)
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
Market Cap
$748.60M
Quick Ratio (Acid-Test)
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$759.58M
Quick Ratio (Acid-Test)
1.52
TTM Avg
0.88
3Y Avg
1.36
5Y Avg
2.75
Market Cap
$768.46M
Quick Ratio (Acid-Test)
13.29
TTM Avg
5.16
3Y Avg
5.49
5Y Avg
4.89
Market Cap
$769.83M
Quick Ratio (Acid-Test)
5.16
TTM Avg
4.89
3Y Avg
3.82
5Y Avg
4.31
Market Cap
$725.68M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.81
3Y Avg
5.95
5Y Avg
7.14
Market Cap
$722.25M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$721.69M
Quick Ratio (Acid-Test)
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $750.73M | 18.86 | 20.42 | 25.97 | 29.52 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $750.01M | 9.39 | 11.79 | 11.79 | 11.79 |
| Candel Therapeutics, Inc. (CADL)vs › | $748.60M | 16.09 | 8.04 | 7.87 | 9.13 |
| Mesa Laboratories, Inc. (MLAB)vs › | $759.58M | 1.52 | 0.88 | 1.36 | 2.75 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | 13.29 | 5.16 | 5.49 | 4.89 |
| Geron Corporation (GERN)vs › | $769.83M | 5.16 | 4.89 | 3.82 | 4.31 |
| Cytek Biosciences, Inc. (CTKB)vs › | $725.68M | 3.86 | 4.81 | 5.95 | 7.14 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $722.25M | 19.31 | 14.05 | 7.67 | 5.91 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | 0.95 | 4.92 | 2.98 | 5.72 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | 3.86 | 4.02 | 3.56 | 3.80 |
Quick Ratio
18.86
Excludes inventory
Current Ratio
18.86
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 18.86 |
| 2026-03-31 | 22.28 |
| 2025-12-31 | 17.14 |
| 2025-09-30 | 18.71 |
| 2025-06-30 | 25.13 |
| 2025-03-31 | 28.37 |
| 2024-12-31 | 29.31 |
| 2024-09-30 | 34.61 |
| 2024-06-30 | 41.42 |
| 2024-03-31 | 38.61 |
| 2023-12-31 | 29.58 |
| 2023-09-30 | 23.77 |
| 2023-06-30 | 25.22 |
| 2023-03-31 | 35.25 |
| 2022-12-31 | 31.10 |
| 2022-09-30 | 33.47 |
| 2022-06-30 | 48.96 |
| 2022-03-31 | 68.22 |
| 2021-12-31 | 72.96 |
| 2021-09-30 | 71.81 |
| 2021-06-30 | 118.91 |
| 2021-03-31 | 111.10 |
| 2020-12-31 | 15.55 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
